Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation

Vassili Panagides; David del Val; Mohamed Abdel-Wahab; Norman Mangner; Eric Durand; Nikolaj Ihlemann; Marina Urena; Costanza Pellegrini; Francesco Giannini; Piotr Scislo; Zenon Huczek; Martin Landt; Vincent Auffret; Jan Malte Sinning; Asim N. Cheema; Luis Nombela-Franco; Chekrallah Chamandi; Francisco Campelo-Parada; Erika Munoz-Garcia; Howard C. Herrmann; Luca Testa; Won Keun Kim; Juan Carlos Castillo; Alberto Alperi; Didier Tchetche; Antonio L. Bartorelli; Samir Kapadia; Stefan Stortecky; Ignacio Amat-Santos; Harindra C. Wijeysundera; John Lisko; Enrique Gutiérrez-Ibanes; Vicenç Serra; Luisa Salido; Abdullah Alkhodair; Ugolino Livi; Tarun Chakravarty; Stamatios Lerakis; Victoria Vilalta; Ander Regueiro; Rafael Romaguera; Utz Kappert; Marco Barbanti; Jean Bernard Masson; Frédéric Maes; Claudia Fiorina; Antonio Miceli; Susheel Kodali; Henrique B. Ribeiro; Jose Armando Mangione; Fabio Sandoli de Brito; Guglielmo Mario Actis Dato; Francesco Rosato; Maria Cristina Ferreira; Valter Correia de Lima; Alexandre Siciliano Colafranceschi; Alexandre Abizaid; Marcos Antonio Marino; Vinicius Esteves; Julio Andrea; Roger R. Godinho; Fernando Alfonso; Helene Eltchaninoff; Lars Søndergaard; Dominique Himbert; Oliver Husser; Azeem Latib; Hervé Le Breton; Clement Servoz; Isaac Pascual; Saif Siddiqui; Paolo Olivares; Rosana Hernandez-Antolin; John G. Webb; Sandro Sponga; Raj Makkar; Annapoorna S. Kini; Marouane Boukhris; Philippe Gervais; Axel Linke; Lisa Crusius; David Holzhey; Josep Rodés-Cabau

doi:10.1016/j.amjcard.2022.02.034

Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation

Vassili Panagides, David del Val, Mohamed Abdel-Wahab, Norman Mangner, Eric Durand, Nikolaj Ihlemann, Marina Urena, Costanza Pellegrini, Francesco Giannini, Piotr Scislo, Zenon Huczek, Martin Landt, Vincent Auffret, Jan Malte Sinning, Asim N. Cheema, Luis Nombela-Franco, Chekrallah Chamandi, Francisco Campelo-Parada, Erika Munoz-Garcia, Howard C. HerrmannLuca Testa, Won Keun Kim, Juan Carlos Castillo, Alberto Alperi, Didier Tchetche, Antonio L. Bartorelli, Samir Kapadia, Stefan Stortecky, Ignacio Amat-Santos, Harindra C. Wijeysundera, John Lisko, Enrique Gutiérrez-Ibanes, Vicenç Serra, Luisa Salido, Abdullah Alkhodair, Ugolino Livi, Tarun Chakravarty, Stamatios Lerakis, Victoria Vilalta, Ander Regueiro, Rafael Romaguera, Utz Kappert, Marco Barbanti, Jean Bernard Masson, Frédéric Maes, Claudia Fiorina, Antonio Miceli, Susheel Kodali, Henrique B. Ribeiro, Jose Armando Mangione, Fabio Sandoli de Brito, Guglielmo Mario Actis Dato, Francesco Rosato, Maria Cristina Ferreira, Valter Correia de Lima, Alexandre Siciliano Colafranceschi, Alexandre Abizaid, Marcos Antonio Marino, Vinicius Esteves, Julio Andrea, Roger R. Godinho, Fernando Alfonso, Helene Eltchaninoff, Lars Søndergaard, Dominique Himbert, Oliver Husser, Azeem Latib, Hervé Le Breton, Clement Servoz, Isaac Pascual, Saif Siddiqui, Paolo Olivares, Rosana Hernandez-Antolin, John G. Webb, Sandro Sponga, Raj Makkar, Annapoorna S. Kini, Marouane Boukhris, Philippe Gervais, Axel Linke, Lisa Crusius, David Holzhey, Josep Rodés-Cabau

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Scarce data exist on mitral valve (MV) infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). This multicenter study included a total of 579 patients with a diagnosis of definite IE after TAVI from the IE after TAVI International Registry and aimed to evaluate the incidence, characteristics, management, and outcomes of MV-IE after TAVI. A total of 86 patients (14.9%) had MV-IE. These patients were compared with 284 patients (49.1%) with involvement of the transcatheter heart valve (THV) only. Two factors were found to be associated with MV-IE: the use of self-expanding valves (adjusted odds ratio 2.49, 95% confidence interval [CI] 1.23 to 5.07, p = 0.012), and the presence of an aortic regurgitation ≥2 at discharge (adjusted odds ratio 3.33; 95% CI 1.43 to 7.73, p <0.01). There were no differences in IE timing and causative microorganisms between groups, but surgical management was significantly lower in patients with MV-IE (6.0%, vs 21.6% in patients with THV-IE, p = 0.001). All-cause mortality rates at 2-year follow-up were high and similar between patients with MV-IE (51.4%, 95% CI 39.8 to 64.1) and patients with THV-IE (51.5%, 95% CI 45.4 to 58.0) (log-rank p = 0.295). The factors independently associated with increased mortality risk in patients with MV-IE were the occurrence of heart failure (adjusted p <0.001) and septic shock (adjusted p <0.01) during the index hospitalization. One of 6 IE episodes after TAVI is localized on the MV. The implantation of a self-expanding THV and the presence of an aortic regurgitation ≥2 at discharge were associated with MV-IE. Patients with MV-IE were rarely operated on and had a poor prognosis at 2-year follow-up.

Original language	English (US)
Pages (from-to)	90-97
Number of pages	8
Journal	American Journal of Cardiology
Volume	172
DOIs	https://doi.org/10.1016/j.amjcard.2022.02.034
State	Published - Jun 1 2022
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.amjcard.2022.02.034

Cite this

Panagides, V., del Val, D., Abdel-Wahab, M., Mangner, N., Durand, E., Ihlemann, N., Urena, M., Pellegrini, C., Giannini, F., Scislo, P., Huczek, Z., Landt, M., Auffret, V., Sinning, J. M., Cheema, A. N., Nombela-Franco, L., Chamandi, C., Campelo-Parada, F., Munoz-Garcia, E., ... Rodés-Cabau, J. (2022). Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation. American Journal of Cardiology, 172, 90-97. https://doi.org/10.1016/j.amjcard.2022.02.034

Panagides, V, del Val, D, Abdel-Wahab, M, Mangner, N, Durand, E, Ihlemann, N, Urena, M, Pellegrini, C, Giannini, F, Scislo, P, Huczek, Z, Landt, M, Auffret, V, Sinning, JM, Cheema, AN, Nombela-Franco, L, Chamandi, C, Campelo-Parada, F, Munoz-Garcia, E, Herrmann, HC, Testa, L, Kim, WK, Castillo, JC, Alperi, A, Tchetche, D, Bartorelli, AL, Kapadia, S, Stortecky, S, Amat-Santos, I, Wijeysundera, HC, Lisko, J, Gutiérrez-Ibanes, E, Serra, V, Salido, L, Alkhodair, A, Livi, U, Chakravarty, T, Lerakis, S, Vilalta, V, Regueiro, A, Romaguera, R, Kappert, U, Barbanti, M, Masson, JB, Maes, F, Fiorina, C, Miceli, A, Kodali, S, Ribeiro, HB, Mangione, JA, Brito, FSD, Dato, GMA, Rosato, F, Ferreira, MC, de Lima, VC, Colafranceschi, AS, Abizaid, A, Marino, MA, Esteves, V, Andrea, J, Godinho, RR, Alfonso, F, Eltchaninoff, H, Søndergaard, L, Himbert, D, Husser, O, Latib, A, Breton, HL, Servoz, C, Pascual, I, Siddiqui, S, Olivares, P, Hernandez-Antolin, R, Webb, JG, Sponga, S, Makkar, R, Kini, AS, Boukhris, M, Gervais, P, Linke, A, Crusius, L, Holzhey, D & Rodés-Cabau, J 2022, 'Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation', American Journal of Cardiology, vol. 172, pp. 90-97. https://doi.org/10.1016/j.amjcard.2022.02.034

@article{5c343e9c09ad455182972ab725d9fdba,

title = "Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation",

abstract = "Scarce data exist on mitral valve (MV) infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). This multicenter study included a total of 579 patients with a diagnosis of definite IE after TAVI from the IE after TAVI International Registry and aimed to evaluate the incidence, characteristics, management, and outcomes of MV-IE after TAVI. A total of 86 patients (14.9%) had MV-IE. These patients were compared with 284 patients (49.1%) with involvement of the transcatheter heart valve (THV) only. Two factors were found to be associated with MV-IE: the use of self-expanding valves (adjusted odds ratio 2.49, 95% confidence interval [CI] 1.23 to 5.07, p = 0.012), and the presence of an aortic regurgitation ≥2 at discharge (adjusted odds ratio 3.33; 95% CI 1.43 to 7.73, p <0.01). There were no differences in IE timing and causative microorganisms between groups, but surgical management was significantly lower in patients with MV-IE (6.0%, vs 21.6% in patients with THV-IE, p = 0.001). All-cause mortality rates at 2-year follow-up were high and similar between patients with MV-IE (51.4%, 95% CI 39.8 to 64.1) and patients with THV-IE (51.5%, 95% CI 45.4 to 58.0) (log-rank p = 0.295). The factors independently associated with increased mortality risk in patients with MV-IE were the occurrence of heart failure (adjusted p <0.001) and septic shock (adjusted p <0.01) during the index hospitalization. One of 6 IE episodes after TAVI is localized on the MV. The implantation of a self-expanding THV and the presence of an aortic regurgitation ≥2 at discharge were associated with MV-IE. Patients with MV-IE were rarely operated on and had a poor prognosis at 2-year follow-up.",

author = "Vassili Panagides and {del Val}, David and Mohamed Abdel-Wahab and Norman Mangner and Eric Durand and Nikolaj Ihlemann and Marina Urena and Costanza Pellegrini and Francesco Giannini and Piotr Scislo and Zenon Huczek and Martin Landt and Vincent Auffret and Sinning, {Jan Malte} and Cheema, {Asim N.} and Luis Nombela-Franco and Chekrallah Chamandi and Francisco Campelo-Parada and Erika Munoz-Garcia and Herrmann, {Howard C.} and Luca Testa and Kim, {Won Keun} and Castillo, {Juan Carlos} and Alberto Alperi and Didier Tchetche and Bartorelli, {Antonio L.} and Samir Kapadia and Stefan Stortecky and Ignacio Amat-Santos and Wijeysundera, {Harindra C.} and John Lisko and Enrique Guti{\'e}rrez-Ibanes and Vicen{\c c} Serra and Luisa Salido and Abdullah Alkhodair and Ugolino Livi and Tarun Chakravarty and Stamatios Lerakis and Victoria Vilalta and Ander Regueiro and Rafael Romaguera and Utz Kappert and Marco Barbanti and Masson, {Jean Bernard} and Fr{\'e}d{\'e}ric Maes and Claudia Fiorina and Antonio Miceli and Susheel Kodali and Ribeiro, {Henrique B.} and Mangione, {Jose Armando} and Brito, {Fabio Sandoli de} and Dato, {Guglielmo Mario Actis} and Francesco Rosato and Ferreira, {Maria Cristina} and {de Lima}, {Valter Correia} and Colafranceschi, {Alexandre Siciliano} and Alexandre Abizaid and Marino, {Marcos Antonio} and Vinicius Esteves and Julio Andrea and Godinho, {Roger R.} and Fernando Alfonso and Helene Eltchaninoff and Lars S{\o}ndergaard and Dominique Himbert and Oliver Husser and Azeem Latib and Breton, {Herv{\'e} Le} and Clement Servoz and Isaac Pascual and Saif Siddiqui and Paolo Olivares and Rosana Hernandez-Antolin and Webb, {John G.} and Sandro Sponga and Raj Makkar and Kini, {Annapoorna S.} and Marouane Boukhris and Philippe Gervais and Axel Linke and Lisa Crusius and David Holzhey and Josep Rod{\'e}s-Cabau",

note = "Funding Information: Dr. Rod{\'e}s-Cabau holds the Research Chair {"}Fondation Famille Jacques Larivi{\`e}re{"} for the Development of Structural Heart Disease Interventions. Dr. Panagides has received a research grant from the “Mediterranean Academic Research and Studies in Cardiology” association (MARS Cardio). Funding: None Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = jun,

day = "1",

doi = "10.1016/j.amjcard.2022.02.034",

language = "English (US)",

volume = "172",

pages = "90--97",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation

AU - Panagides, Vassili

AU - del Val, David

AU - Abdel-Wahab, Mohamed

AU - Mangner, Norman

AU - Durand, Eric

AU - Ihlemann, Nikolaj

AU - Urena, Marina

AU - Pellegrini, Costanza

AU - Giannini, Francesco

AU - Scislo, Piotr

AU - Huczek, Zenon

AU - Landt, Martin

AU - Auffret, Vincent

AU - Sinning, Jan Malte

AU - Cheema, Asim N.

AU - Nombela-Franco, Luis

AU - Chamandi, Chekrallah

AU - Campelo-Parada, Francisco

AU - Munoz-Garcia, Erika

AU - Herrmann, Howard C.

AU - Testa, Luca

AU - Kim, Won Keun

AU - Castillo, Juan Carlos

AU - Alperi, Alberto

AU - Tchetche, Didier

AU - Bartorelli, Antonio L.

AU - Kapadia, Samir

AU - Stortecky, Stefan

AU - Amat-Santos, Ignacio

AU - Wijeysundera, Harindra C.

AU - Lisko, John

AU - Gutiérrez-Ibanes, Enrique

AU - Serra, Vicenç

AU - Salido, Luisa

AU - Alkhodair, Abdullah

AU - Livi, Ugolino

AU - Chakravarty, Tarun

AU - Lerakis, Stamatios

AU - Vilalta, Victoria

AU - Regueiro, Ander

AU - Romaguera, Rafael

AU - Kappert, Utz

AU - Barbanti, Marco

AU - Masson, Jean Bernard

AU - Maes, Frédéric

AU - Fiorina, Claudia

AU - Miceli, Antonio

AU - Kodali, Susheel

AU - Ribeiro, Henrique B.

AU - Mangione, Jose Armando

AU - Brito, Fabio Sandoli de

AU - Dato, Guglielmo Mario Actis

AU - Rosato, Francesco

AU - Ferreira, Maria Cristina

AU - de Lima, Valter Correia

AU - Colafranceschi, Alexandre Siciliano

AU - Abizaid, Alexandre

AU - Marino, Marcos Antonio

AU - Esteves, Vinicius

AU - Andrea, Julio

AU - Godinho, Roger R.

AU - Alfonso, Fernando

AU - Eltchaninoff, Helene

AU - Søndergaard, Lars

AU - Himbert, Dominique

AU - Husser, Oliver

AU - Latib, Azeem

AU - Breton, Hervé Le

AU - Servoz, Clement

AU - Pascual, Isaac

AU - Siddiqui, Saif

AU - Olivares, Paolo

AU - Hernandez-Antolin, Rosana

AU - Webb, John G.

AU - Sponga, Sandro

AU - Makkar, Raj

AU - Kini, Annapoorna S.

AU - Boukhris, Marouane

AU - Gervais, Philippe

AU - Linke, Axel

AU - Crusius, Lisa

AU - Holzhey, David

AU - Rodés-Cabau, Josep

N1 - Funding Information: Dr. Rodés-Cabau holds the Research Chair "Fondation Famille Jacques Larivière" for the Development of Structural Heart Disease Interventions. Dr. Panagides has received a research grant from the “Mediterranean Academic Research and Studies in Cardiology” association (MARS Cardio). Funding: None Publisher Copyright: © 2022 Elsevier Inc.

PY - 2022/6/1

Y1 - 2022/6/1

N2 - Scarce data exist on mitral valve (MV) infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). This multicenter study included a total of 579 patients with a diagnosis of definite IE after TAVI from the IE after TAVI International Registry and aimed to evaluate the incidence, characteristics, management, and outcomes of MV-IE after TAVI. A total of 86 patients (14.9%) had MV-IE. These patients were compared with 284 patients (49.1%) with involvement of the transcatheter heart valve (THV) only. Two factors were found to be associated with MV-IE: the use of self-expanding valves (adjusted odds ratio 2.49, 95% confidence interval [CI] 1.23 to 5.07, p = 0.012), and the presence of an aortic regurgitation ≥2 at discharge (adjusted odds ratio 3.33; 95% CI 1.43 to 7.73, p <0.01). There were no differences in IE timing and causative microorganisms between groups, but surgical management was significantly lower in patients with MV-IE (6.0%, vs 21.6% in patients with THV-IE, p = 0.001). All-cause mortality rates at 2-year follow-up were high and similar between patients with MV-IE (51.4%, 95% CI 39.8 to 64.1) and patients with THV-IE (51.5%, 95% CI 45.4 to 58.0) (log-rank p = 0.295). The factors independently associated with increased mortality risk in patients with MV-IE were the occurrence of heart failure (adjusted p <0.001) and septic shock (adjusted p <0.01) during the index hospitalization. One of 6 IE episodes after TAVI is localized on the MV. The implantation of a self-expanding THV and the presence of an aortic regurgitation ≥2 at discharge were associated with MV-IE. Patients with MV-IE were rarely operated on and had a poor prognosis at 2-year follow-up.

AB - Scarce data exist on mitral valve (MV) infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). This multicenter study included a total of 579 patients with a diagnosis of definite IE after TAVI from the IE after TAVI International Registry and aimed to evaluate the incidence, characteristics, management, and outcomes of MV-IE after TAVI. A total of 86 patients (14.9%) had MV-IE. These patients were compared with 284 patients (49.1%) with involvement of the transcatheter heart valve (THV) only. Two factors were found to be associated with MV-IE: the use of self-expanding valves (adjusted odds ratio 2.49, 95% confidence interval [CI] 1.23 to 5.07, p = 0.012), and the presence of an aortic regurgitation ≥2 at discharge (adjusted odds ratio 3.33; 95% CI 1.43 to 7.73, p <0.01). There were no differences in IE timing and causative microorganisms between groups, but surgical management was significantly lower in patients with MV-IE (6.0%, vs 21.6% in patients with THV-IE, p = 0.001). All-cause mortality rates at 2-year follow-up were high and similar between patients with MV-IE (51.4%, 95% CI 39.8 to 64.1) and patients with THV-IE (51.5%, 95% CI 45.4 to 58.0) (log-rank p = 0.295). The factors independently associated with increased mortality risk in patients with MV-IE were the occurrence of heart failure (adjusted p <0.001) and septic shock (adjusted p <0.01) during the index hospitalization. One of 6 IE episodes after TAVI is localized on the MV. The implantation of a self-expanding THV and the presence of an aortic regurgitation ≥2 at discharge were associated with MV-IE. Patients with MV-IE were rarely operated on and had a poor prognosis at 2-year follow-up.

UR - http://www.scopus.com/inward/record.url?scp=85127518827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127518827&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2022.02.034

DO - 10.1016/j.amjcard.2022.02.034

M3 - Article

C2 - 35387738

AN - SCOPUS:85127518827

SN - 0002-9149

VL - 172

SP - 90

EP - 97

JO - American Journal of Cardiology

JF - American Journal of Cardiology

ER -

Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this